Importance of <i>SPP1</i> genotype as a covariate in clinical trials in Duchenne muscular dystrophy

Abstract

These data provide evidence of the role of SPP1 genotype as a disease modifier in DMD and support its relevance in the selection of homogeneous groups of patients for future clinical trials.